| Literature DB >> 30081573 |
Abstract
Cancer is the second biggest cause of death worldwide. Despite a number of studies being conducted, the effective mechanism for treating cancer has not yet been fully understood. The tumor-microenvironment such as hypoxia, low nutrients could disturb function of endoplasmic reticulum (ER) to maintain cellular homeostasis, ultimately leading to the accumulation of unfolded proteins in ER, so-called ER stress. The ER stress has a close relation with cancer. ER stress initiates unfolded protein response (UPR) to re-establish ER homeostasis as an adaptive pathway in cancer. However, persistent ER stress triggers the apoptotic pathway. Therefore, blocking the adaptive pathway of ER stress or facilitating the apoptotic pathway could be an anti-cancer strategy. Recently, natural products and their derivatives have been reported to have anti-cancer effects via ER stress. Here, we address mechanisms of ER stress-mediated apoptosis and highlight strategies for cancer therapy by utilizing ER stress. Furthermore, we summarize anti-cancer activity of the natural products via ER stress in six major types of cancers globally (lung, breast, colorectal, gastric, prostate and liver cancer). This review deepens the understanding of ER stress mechanisms in major cancers as well as the suppressive impact of natural products against cancers via ER stress.Entities:
Keywords: apoptosis; bioactive compounds; cancer; endoplasmic-reticulum stress; natural products; unfolded protein response
Mesh:
Substances:
Year: 2018 PMID: 30081573 PMCID: PMC6115829 DOI: 10.3390/nu10081021
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Adaptive pathways of endoplasmic reticulum (ER) stress. ER stress is induced by an accumulation of unfolded proteins in the ER lumen. During ER stress, glucose-regulated protein 78 (GRP78)/ binding protein (BiP) dissociates from its interaction with the three ER stress sensors, inositol-requiring protein 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6), which become activated. IRE1 mediates splicing of α-x-box binding protein 1 (XBP1), which is responsible for the upregulation of ER associated degradation (ERAD). PERK phosphorylates eIF2α and induce activating transcription factor 4 (ATF4), which is involved in restoring ER homeostasis. ATF6α cleaved by specific Golgi resident proteases, increase expression of UPR genes and ERAD. Eukaryotic initiation factor 2 (eIf2); protein kinase RNA-like ER kinase (PERK).
Figure 2Apoptotic pathways of ER stress. If the adaptive UPR pathway fails to restore homeostasis, chronic ER stress induces apoptosis pathways. ER stress activates IRE1 and activated IRE recruits TNF receptor-associated factor2 (TRAF2) and apoptosis signal-regulating kinase 1 (ASK1). TRAF2 stimulates the activation of caspase-12 and ASK1 elicits the phosphorylation of c-Jun-N terminal kinase (JNK) to activate the pro-apoptotic protein; Bcl-2-like protein 11 (BIM), Bak, Bax and inhibits the anti-apoptotic protein; B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax). Activation of PERK and ATF6 leads to up-regulation of CHOP that regulates Gadd34, ERO1α and activates the pro-apoptotic protein; BIM, Bak, Bax, p53 upregulated modulator of apoptosis (PUMA), NOXA as well as DR which increase caspase-8. Also, ER stress generates ROS and this facilitates the accumulation of unfolded protein in the ER. ER stress-induced Ca2+ release into cytosol leads to depolarization of the inner mitochondrial membrane, resulting in Mitochondrial ROS. Apoptosis protease-activating factor 1 (Apaf1); FAS-associated death domain (FADD).
Bioactive compounds from natural products that induce ER-stress-mediated apoptosis in lung cancer.
| Family Name | Compound | Cell Line | Duration/Dosage | Mechanism | Reference |
|---|---|---|---|---|---|
|
| Polyphyllin D | NCI-H460 | 1.8 µM, 8 h | CHOP ↑, GRP78/BiP ↑, PDI ↑ | [ |
| cleavage of caspase-3,-4,-9,-12 ↑, Bax ↑, Bcl-2 ↓ | |||||
| Dehydrocostuslactone | NCI-H460 | 15 μg/mL, 1 h | release of intracellular Ca2+ levels ↑, Δψm ↓, p-PERK ↑, GRP78/BiP ↑, IRE1 ↑, CHOP ↑, XBP-1 ↑ | [ | |
| Cleavage of caspase-4 ↑, JNK ↑, MAPK ↑ | |||||
| ROS ↑ | |||||
| A549 | 15 μg/mL, 1 h | release of intracellular Ca2+ ↑, Δψm ↓,p-PERK ↑, GRP78/BiP ↑, IRE1 ↑, CHOP ↑, XBP1 ↑ | |||
| JNK ↑, MAPK ↑, cleavage of caspase-4 ↑ | |||||
| ROS ↑ | |||||
| BrefeldinA | A549 | 1 µM, 36 h | p-PERK ↑, IRE1α ↑, ATF4 ↑, ATF6 ↑, CHOP ↑, GRP78/BiP ↑ | [ | |
| cleavage of PARP ↑, cleavage of caspase-2 ↑, Bid ↑ | |||||
|
| ω-Hydroxyundec-9-enoic acid | H1299 | 500 µM, 24 h | p-eIF2α ↑, CHOP ↑ | [ |
| cleavage of caspase-6,-9 ↑, cleavage of PARP ↑ | |||||
| ROS ↑ | |||||
|
| Curcumin | NCI-H460 | 25 µM, 24 h | release of intracellular Ca2+ ↑, Δψm ↓, CHOP ↑, GRP78/BiP ↑ | [ |
| Bcl-2 ↓, Bcl-xL ↓, cytochrome c ↑, cleavage of caspase-3,-8,-9 ↑, | |||||
| ROS ↑ | |||||
| Cantharidin | H460 | 10 µM, 24 h | release of intracellular Ca2+ ↑, Δψm ↓, GRP78/BiP ↑, IRE1α ↑, IRE1β ↑, ATF6α ↑, XBP1 ↑, calpain ↑, | [ | |
| Bcl-xL ↓, cleavage of caspase-3,-8,-4 ↑ cytochrome c ↑ | |||||
| ROS ↑ | |||||
|
| Furanodiene | A549, 95-D | 80 µM, 24 h | CHOP ↑, BIP ↑ | [ |
| Parthenolide | A549, Calu-1, H1299, H1792 | 20 µM, 24 h | ATF4 ↑, p-eIF2a ↑, eIF2α ↑ | [ | |
| cleavage of caspase-3,-8,-9 ↑, cleavage of PARP ↑ | |||||
|
| Anacardic acid | A549 | 3.0 μg/mL, 18 h | release of intracellular Ca2+ ↑, Δψm ↓, GRP78/BiP ↑, CHOP ↑, IRE1α ↑ ATF6 ↑, p-PERK ↓, p-eIF2α ↓ | [ |
| cleavage caspase-12 ↑ |
Glucose-regulated protein 78 (GRP78); binding protein (BiP); protein disulphide isomerase (PDI); protein kinase RNA-like ER kinase (PERK); reactive oxygen species (ROS); inositol-requiring protein 1 (IRE1); ↑ - increasing concentration; ↓ - decreasing concentration; activating transcription factor 4 (ATF4); activating transcription factor 6 (ATF6); B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax); X-ox binding protein 1 (XBP-1); c-Jun-N terminal kinase (JNK); mitochondrial membrane potential (Δψm); C/EBP-homologous protein (CHOP); α-x-box binding protein 1 (XBP1); apoptosis-inducing factor (AIF); and eukaryotic initiation factor 2 (eIf2).
Bioactive compounds from natural products that induce ER stress-mediated apoptosis in breast cancer.
| Family Name | Compound | Cell Line | Duration/Dosage | Mechanism | Reference |
|---|---|---|---|---|---|
|
| Brefeldin A | MDA-MB-231 | 1 μg/mL, 24 h | IRE1α ↑, PERK ↑, CHOP ↑, calnexin ↓ | [ |
| BIM ↑, cleavage of PARP ↑, Bcl-2 ↓, | |||||
| Cryptotanshinone | MCF7 | 10 µM, 24 h | p-eIF2α ↑, GRP94 ↑, GRP78 ↑, CHOP ↑ | [ | |
| cleavage of PARP ↑, cleavage of caspase3 ↓ | |||||
| ROS ↑ | |||||
|
| Saxifragifolin | MDA-MB-231 | 5 µM, 24 h | IRE1α ↑, calnexin ↑, calpain ↑, XBP1 ↑, CHOP ↑, GRP78/BiP ↑, | [ |
| cleavage of PARP ↑, cleavage of caspase-3,-9 ↑, Bax ↑, cytochrome C ↑, p-JNK ↑ | |||||
| ROS ↑ | |||||
| MCF7 | 5 µM, 24 h | IRE1α ↑, Calnexin ↑, calpain ↑, XBP-1 ↑, GRP78/BiP ↑, CHOP ↑ | |||
| cytochrome c ↑ | |||||
|
| Prodigiosin | MCF7 MDA-MB-231T-47D | 100 µM, 24 h | GRP78 ↑, CHOP ↑, p-IRE1 ↑, IRE1 ↑, p-eIF2a ↑, eIF2a ↑, ATF6 ↑ | [ |
| cleavage of PARP ↑, p-JNK ↑, JNK ↑, BCL-2 ↓ | |||||
|
| Fucoidan | MDA-MB-231 | 100 μg/mL, 72 h | CHOP ↑, ATF4 ↑, p-eIF2α ↑, GRP78/BiP ↓, p-IRE1 ↓, XBP1 ↓ | [ |
| Bax ↑, CaMK II ↑, cleavage of caspase-3,-12 ↑, cleavage of PARP ↑ | |||||
| γ-tocotrienol | MDA-MB-231 | 40 µM, 16 h | CHOP ↑, ATF4 ↑, GRP78/BiP ↑, XBP1 ↑ | [ | |
| cleavage of PARP ↑, cleavage of caspase-3,-8,-9 ↑, DR5 ↑, JNK ↑, p-JNK, C-Jun ↑, p38 MAPK ↑ | |||||
| MCF-7 | 40 µM, 16 h | CHOP ↑, GRP78/BiP ↑, XBP1 ↑ | |||
| cleavage of PARP ↑, cleavage of caspase-8,-9 ↑, JNK ↑, p-JNK ↑, C-Jun ↑, DR5 ↑, p38 MAPK ↑ | |||||
| Brazilian Red propolis | Ethanol extract of Brazilian Red propolis | MCF-7 | 20 μg/mL, 24 h | CHOP ↑ | [ |
| cleavage of caspase-3 ↑, Bax ↑, BcL-xL ↓, BcL-2 ↓ | |||||
|
| Ampelopsin | MCF-7 MDA-MB-231 | 60 µM, 24 h | GRP78/BiP ↑, p-PERK ↑, p-eIF2α ↑, ATF6 ↑, CHOP ↑ | [ |
| ROS ↑ |
Bcl-2-like protein 11 (BIM); death receptor (DR5).
Bioactive compounds from natural products that induce ER stress-mediated apoptosis in colorectal cancer.
| Family Name | Compound | Cell Line | Duration/Dosage | Mechanism | Reference |
|---|---|---|---|---|---|
|
| Curcumin | HT-29 | 40 μM, 24 h | release of intracellular Ca2+, Δψm ↓, CHOP ↑ | [ |
| cleavage of caspase-3,-7,-8,-9 ↑, Fas ↑, FasL ↑ FADD ↑ Bid ↑, tBid ↑, p-JNK ↑, Bax ↑, cytochrome c ↑, Bcl-2 ↓ | |||||
|
| 2-3,4 dihydroxyphenylethanol | HT-29 | 400 μM, 16 h, | release of intracellular Ca2+ ↑, Δψm ↓, IRE1 ↑, XBP1 ↑, GRP78/BiP ↑, PERK ↑, eIF2α ↑, CHOP ↑, | [ |
| Bax ↑, Bak ↑, Bad ↑, cytochrome c ↑, cleavage of caspase 3 ↑, TRAF2 ↑, ASK ↑, JNK ↑, AP-1 ↑, p-JNK ↑ C-jun ↑, PI3K/Akt ↓, Bcl-2 ↓ | |||||
|
| Brefeldin A (BFA) | Colo 205 | 15 ng/mL, 24 h | GRP78 ↑, XBP1 ↑, CHOP ↑ | [ |
| Resveratrol | HT29 | 50 μM, 24 h | GRP78/BiP ↑, CHOP ↑, XBP1 ↑, eIF2α ↑ | [ | |
| cleavage of caspase-4 ↑, cleavage of PARP ↑ | |||||
| Zerumbone | HCT116-p53null | 20 μM, 24 h | ATF4 ↑, CHOP ↑, GRP78/BiP ↑, p-PERK ↑, PERK ↑ eIF2α ↑, p-eIF2α ↑ | [ | |
| DR5 ↑ | |||||
| ROS ↑ | |||||
| SW480 | 20 μM, 24 h | ATF4 ↑, CHOP ↑, GRP78/BiP ↑, p-PERK ↑, PERK ↑ eIF2α ↑, p-eIF2α ↑ | |||
| DR5 ↑ | |||||
| ROS ↑ | |||||
|
| Guttiferone H | HCT116 | 10 μg/mL, 24 h | ATF4 ↑, XBP1 ↑, CHOP ↑ | [ |
| Cleavage of caspases-3,-7 ↑ | |||||
| Fucoidan | HCT116 | 100 μg/mL, 72 h | GRP78↑, p-CaMKII ↑, eIF2a ↑, p-eIF2α ↑, CHOP ↑, IRE1 ↓, XBP1 ↓ | [ | |
| Cleavage of PARP ↑ | |||||
| Piperine | HT-29 | 100 μg/mL, 72 h | IRE1α ↑, CHOP ↑, GPR78/BiP ↑ | [ | |
| cleavage of PARP ↑, cytochrome c ↑, JNK ↑, MAPK ↑, PI3K/Akt ↓ | |||||
| ROS ↑ | |||||
| Flavokawain B | HCT116 | 50 μM, 8 h | CHOP ↑, ATF4 ↑ | [ | |
| Bcl-2 ↓, MAPK ↑, PARP ↑, cytochrome c ↑, BIM ↑, Bak ↑ | |||||
| ROS ↑ |
TNF receptor-associated factor2 (TRAF2); apoptosis signal-regulating kinase 1 (ASK1); calcium/calmodulin-dependent protein kinase II (CaMKII); Fas ligand (FasL).
Bioactive compounds from natural products that induce ER stress-mediated apoptosis in gastric cancer.
| Family Name | Compound | Cell Line | Duration/Dosage | Mechanism | Reference |
|---|---|---|---|---|---|
|
| Curcumin | AGS | 20 µM, 24 h | Release of intracellular Ca2+ ↑, Δψm ↓, CHOP ↑ | [ |
| cleavage of caspase-3,-7,-8,-9 ↑, cytochrome c ↑ | |||||
| Ultrafine | SNU-1 | 200 μg/mL, 24 h | GRP78/BiP ↑, p-eIF2α ↑ | [ | |
| cleavage caspase-3,-6,-9 ↑, cleavage of PARP ↑ | |||||
| SNU-484 | 300 μg/mL, 24 h | p-eIF2α ↑, GRP78/BiP ↑ | |||
| cleavage of caspase-3,-6,-9 ↑, cleavage of PARP ↑, Bcl-2 ↓, Bcl-xL ↓ | |||||
|
| Honokiol | MKN45 | 40 µM, 8 h | GRP94 ↓, CHOP ↑, calpain ↑ | [ |
| cleavage of caspase-7,-12 ↑, cleavage of PARP ↑ | |||||
| SCM-1 | 40 µM, 24 h | GRP94 ↓, CHOP ↑, calpain ↑ | |||
| cleavage of PARP ↑, | |||||
| vitamin E | Vitamin E succinate | SGC-7901 | 20 μg/mL, 24 h | release of Intracellular Ca2+ ↑, Δψm ↓ | [ |
| cleavage of caspase-4,-7,-12 ↑, p-JNK ↑, JNK ↑, cleavage of PARP ↑ | |||||
| vitamin E | A-tocopheryl succinate | SGC-7901 | 20 μg/mL, 24 h | GRP78/BiP ↑, CHOP ↑ | [ |
| cleavage of caspase-4 ↑ | |||||
| ROS ↑ | |||||
|
| Casticin | BGC-823 | 1 μmol/mL, 24 h | CHOP ↑, p-eIF2α ↑, eIF2α ↑, GRP78/BiP ↑ | [ |
| DR5 ↑, Bax ↑, Bid ↑, cleavage of caspase-3,-8,-9 ↑ | |||||
| ROS ↑ | |||||
|
| 1-(4-hydroxy-3-methoxyphenyl)-5-(2-nitrophenyl)penta-1,4-dien-3-one (WZ35) | SGC-7901 | 10 μM, 12 h | ATF6 ↑, ATF4 ↑, XBP1 ↑, CHOP ↑ | [ |
| P-JNK ↑, Bax ↑, cleavage of caspase-3 ↑ Bcl-2 ↓ | |||||
| ROS ↑ | |||||
| SGC-7901xenograft in athymic BALB/Ca-nu/nu female mice | WZ35 (orally, 50 mg/kg) for 28 days | CHOP ↑ | |||
| cleavage of caspase-3 ↑ |
Bioactive compounds from natural products that induce ER stress-mediated apoptosis in prostate cancer.
| Family Name | Compound | Cell Line | Duration/Dosage | Mechanism | Reference |
|---|---|---|---|---|---|
| Ardisianone | PC-3 | 10 μg/mL, 24 h | GRP78/BiP ↑ | [ | |
| cleavage ofcaspases-3,-7,-8,-9 ↑, cleavage of PARP ↑, Bcl-2 ↑, Bcl-xL ↑, Bak ↑, Bax ↑, Bid ↑, PI3K/Akt ↓, cytochrome c ↑, AIF ↑ | |||||
| ROS ↑ | |||||
|
| Polyphenon E | PNT1a | 35 μg/mL, 12 h | ATF4 ↑, PERK ↑, p-eIF2α ↑, eIF2α ↑, GRP78/BiP ↑, CHOP ↑, XBP1 ↑ | [ |
| cleavage of caspase-3,-7,-9 ↑, Bak ↑, Puma ↑, cleavage of PARP ↑ | |||||
| ROS ↑ | |||||
| PC3 | 145 μg/mL, 12 h | ATF4 ↑, PERK ↑, p-eIF2α ↑, eIF2α ↑, CHOP ↑, XBP1 ↑, | |||
| cleavage of caspase-3,-7,-9 ↑, Puma ↑, Bak ↑, Bax ↑, PARP ↑ AIF ↑ | |||||
| ROS ↑ | |||||
|
| Mangosteen Fruit Extract | LNCaP | 15 μg/mL, 24 h | PERK ↑, IRE1 ↑, CHOP ↑, GRP78/BiP ↑, Ero1 ↑, ER chaperone ↑, PDI ↑, XBP1 ↑, calnexin ↑ | [ |
| Cleavage of caspase-3,-4 ↑, Bax ↑ | |||||
| 22Rv1 cells | 15 μg/mL, 24 h | PERK ↑, IRE1 ↑, CHOP ↑, GRP78/BiP ↑, Ero1 ↑, ER chaperone ↑, PDI ↑, XBP1 ↑, calnexin ↑ | |||
| Cleavage of caspase-3,-4 ↑, Bax ↑ | |||||
|
| Marchantin M | PC-3 | 10 μm, 48 h | GRP78/BiP ↑, CHOP ↑, XBP-1 ↑, p-eIF2α ↑,eIF2α ↑,ATF4 ↑, ATF6 ↑, ERAD ↓ | [ |
| Cleavage of caspase-3,-4 ↑ | |||||
| DU145 | 10 μM, 48 h | GRP78/BiP ↑, CHOP ↑, XBP1 ↑, p-eIF2α ↑, eIF2α ↑, ATF4 ↑, ATF6 ↑, ERAD ↓ | |||
| Cleavage of caspase-3,-4 ↑ | |||||
| LNCaP | 10 μM, 48 h | GRP78/BiP, CHOP ↑, XBP1 ↑, p-eIF2α ↑, eIF2α ↑, ATF4 ↑, ATF6 ↑, ERAD ↓ | |||
| Cleavage of caspase-3,-4 ↑ | |||||
|
| Monascuspiloin | PC-3 | 25 μM, 48 h | IRE1α ↑, p-eIF2α ↑, eIF2α ↑ | [ |
| Quercetin | PC-3 | 150 μM, 48 h | Release of intracellular Ca2+ ↑, Δψm ↓, GRP78/BiP ↑, ATF4 ↑, IRE1α ↑ ATF6 ↑ | [ | |
| Bid ↓, Bcl-2 ↓, cleavage of caspase-12 ↓Bax ↑, PARP ↑, cytochrome c ↑, AIF ↑, Endo G ↑, cleavage of caspase-3,-8,-9 ↑ | |||||
| Zerumbone | PC-3 | 30 μM, 24 h | Release of intracellular Ca2+ ↑, Δψm ↓, calpain ↑, GRP78, CHOP ↑ | [ | |
| cleavage of caspase-3,-7,-9 ↑, cleavage of PARP ↑, Bid ↑, Bcl-2 ↓ |
ER associated degradation (ERAD).
Bioactive compounds from natural products that induce ER stress-mediated apoptosis in liver cancer.
| Family Name | Compound | Cell Line | Duration/Dosage | Mechanism | Reference |
|---|---|---|---|---|---|
|
| Licochalcone A | HepG2 | 10 μM, 24 h | release of intracellular Ca2+ ↑, Δψm ↓, ATF6 ↑, eIF2α ↑, IRE1α ↑, CHOP ↑, GRP94 ↑, XBP1 ↑, GRP78/BiP ↑ | [ |
| Cleavage of caspases-3,-4,-9 ↑, cleavage of PARP ↑ | |||||
| ROS ↑ | |||||
|
| Guggulsterone | Hep3B | 30 μM, 12 h | Release of intracellular Ca2+ ↑, Δψm ↓, IRE1 ↑, JNK ↑, GRP78/BiP, PERK ↑, eIF2α ↑, ATF4 ↑, CHOP ↑ | [ |
| DR5 ↑, cleavage of caspase-3 ↑, cleavage of PARP ↑ | |||||
| ROS ↑ | |||||
| Verrucarin A | Hep3B | 1 μM, 12 h | GRP78/BiP ↑, p-PERK ↑, p-eIF2α ↑, CHOP ↑ | [ | |
| DR5 ↑, cleavage of caspase-3,-8 ↑, cleavage of PARP ↑ | |||||
| ROS ↑ | |||||
| HepG2 | 1 μM, 12 h | Chop ↑ | |||
| DR 5 ↑ | |||||
| 7-dimethoxyflavone | Hep3B | 5 μmol, 24 h | CHOP ↑, GPR78/BiP ↑, ATF4 ↑ | [ | |
| DR5 ↑, cleavage of caspase-3,-8,-9 ↑ | |||||
| ROS ↑ | |||||
| Neferine | Hep3B | 20 μmol, 24 h | GRP78/BiP ↑, calnexin ↑, PDI ↑, calpain ↑ | [ | |
| cleavage of caspase-3,-6,-7,-8,-12, cleavage of PARP ↑, Puma ↑, BIM ↑, Bid ↑ | |||||
| Paeonol | HepG2 | 31.25 mg/mL, 24 h | GRP78 ↑, CHOP ↑ | [ | |
| cleavage of caspase-3 ↑, PI3K/AKT ↓ | |||||
| Cryptotanshinone | HepG2 | 10 μM, 24 h | eIF2α ↑, GRP94 ↑, GRP78/BiP ↑, cisplatin ↑, CHOP ↑ | [ | |
| cleavage of PARP ↑, JNK ↑, MAPK ↑ | |||||
| ROS ↑ | |||||
| 6-Shogaol | SMMC-7721 | 20 μM, 6 h | GRP94 ↑, GRP78/BiP ↑, CHOP ↑, p-PERK ↑, PERK ↑, eIF2α ↑, p-eIF2α ↑ | [ | |
| cleavage of PARP ↑, cleavage of caspase-3 ↑ | |||||
| SMMC-7721 xenograft in Male SCID mice | 6-shogaol (orally, 10 mg/kg), 28 days | p-PERK ↓, eIF2α ↓, p-eIF2α ↓ | |||
| cleavage of caspase-3 ↑ | |||||
| Genistein | Hep3B | 100 μM, 48 h | release of intracellular Ca2+ ↑, Δψm ↓, calpain ↑, CHOP ↑, GRP78/BiP ↑ | [ | |
| cleavage of caspase-2,-3,-7,-12 ↑, cleavage of PARP ↑, Apaf-1 ↑ cytochrome c ↑, Bad ↑ | |||||
| ROS ↑ |